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patients. For each cohort, we calculated proportions of patients
with T2D using 7 individual insulin regimens (basal only, bolus
only, basal-bolus, basal only with oral anti-diabetic medication
(OAD), bolus only with OAD, basal-bolus with OAD, other).
Chi-square test and Fisher’s exact test were used to examine the
association between patients’ insulin regimens and the specialty
of the physician who initiated their insulin use. Further we used
canonical correspondence analysis to explore the association
between practice specialty and patients’ insulin regimens.
RESULTS: Both the Chi-square statistics (p < 0.0001) and the
Fisher’s exact test (p < 0.000001) indicate that patients’ insulin
regimens are strongly associated with physicians’ practice type.
The canonical correspondence analysis suggest that 86.27% of
principal inertia could be explained by a dimension on which
OAD use is correspond closely with general practitioners,
endocrinologist, and internist practice specialties. The canonical
correspondence analysis results also indicate that physi-
cians’ choice of insulin initiation regimen was statisti-
cally signiﬁcantly associate with their practice specialties.
CONCLUSION: The practice specialty of the physicians initi-
ating insulin is strongly associated with their patients’ overall
insulin regimens. Compared to other physician practice special-
ties, endocrinologists were most likely to prescribe basal-bolus
insulin with OAD, and least likely to prescribe basal only
insulin.
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OBJECTIVE: A recent randomised clinical trial demonstrated
that specialist health professionals (SHP) and volunteer peer
advisors in diabetes (PAD) are equally effective in delivering
training programs for self-management of diabetes, based on a
validated ﬁve-item knowledge questionnaire. The objective of
this study was to compare the costs of training delivered by
SHP and by PAD. METHODS: Cost of SHP (specialist nurse) in
the NHS setting, including their education/training costs, was
obtained from published sources. Cost of training of PAD was
based on actual resource utilization during their training: 33
sessions (including instruction and mentoring) of 90 min each
were needed at cost of time of a SHP trainer per group of 15.
Intervention time for groups of 15 was 6 training session of
90 min each, based on the clinical trial. Patient concordance was
included in the analysis. All costs were for 2007. As many vol-
unteers discontinue their commitment, assumptions as to their
prospective engagement were tested in scenario analysis. Effects
of the voluntary involvement of PAD on their own health and
cost outcomes, and cost consequences of the effects of training
were not considered. RESULTS: The cost per patient completing
the training delivered by SHP was 45.19. The cost for PAD
depended on the number of courses delivered after they have
been trained: for one course scenario, the cost was 21.52, for 3
courses 7.17, and for ﬁve courses 4.30. The respective cost
savings per 1000 patients completing the training were23,673,
38,021, and 40,891. Engaging PAD instead of SHP to train
1000 patients would allow the NHS to provide training on
self-management in diabetes to additional 1100–9500 patients.
CONCLUSION: Engaging volunteer peer advisors in the train-
ing on self-management of diabetes is a highly cost-saving inter-
vention with potentially considerable implications for public
health in the UK.
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OBJECTIVE: Controlling risk factors/using cardioprotective
therapies can reduce cardiovascular (CV) morbidity/mortality
in diabetic patients 1)translating this evidence into practice can
be challenging, and 2) many patients receive inadequate care.
In an effort to help improve the care primary care physicians
provide to patients with Diabetes (DM) in Canada, the Expert-
MDTM CV Diabetes program was developed. To assess the
impact of the ExpertMDTM program in improving physicians’
management of the CV complications of DM patients.
METHODS: A total of 100 Canadian family physicians (FPs)
voluntarily participated in the program. Physicians’ manage-
ment of the CV complications of patients with DM was
assessed before (Pre-) and After (Post-) implementation of the
ExpertMDTM program via self-audit. Clinical data parameters,
gathered via case report forms submitted on-line, examined
State of Care at Visit Entry and Visit Exit, Pre- and Post-
Program. Twenty-four FPs recruited as a control group solely
for the self-audit submitted paper-based forms to the data
centre. Data were cleaned/analyzed by Groupe D’analyse,
Ltee, Montréal, QC. RESULTS: At Visit Entry, more patients
were at BP goal (<130/80) Post program in both FP groups
(ExpertMDTM: 34.3% vs. 29.2%, p = 0.01; Control: 47.5%
vs. 34.3%, p = 0.02). At Visit Exit, Physician management
of glucose (A1c <3 months, 80.8% vs. 77%, p: 0.05), choles-
terol screening <12 months (93.7% vs. 89.5%, p: 0.002), ACR
screening <12 months (95.6% vs. 90.5, p: 0.0004), obesity
screening via waist measurement (28.2% vs. 12.5%, p <
0.0001) and ASA use (86.9% vs. 77.5%, p < 0.0001) was sig-
niﬁcantly higher Post- versus Pre- program for ExpertMDTM
participants. Post- program Control FPs checked BP at ofﬁce
visit (100% vs. 74.9%, p < 0.0001), monitored ACR (92.8%
vs. 83.5%, p = 0.04) and used ASA (96.1% vs. 82.4%, p:
0.0002) signiﬁcantly more often. CONCLUSION: The results
indicate the ExpertMDTM CV Diabetes program positively
impacted physician practice patterns, enhancing the care pro-
vided to DM patients.
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OBJECTIVE: Medical errors are a signiﬁcant and costly problem
in the United States. They kill more Americans each year than
motor vehicle accidents, breast cancer, and AIDS (Institute of
Medicine 1999). Our objective is to develop a Bayesian method
to detect mismatched specimens using blood laboratory data
from the National Health and Nutrition Examination Survey
(NHANES) and to compare this method to an existing auto-
mated rule-based approach, LabRespond. METHODS: The
sample consisted of 6486 participants separated into a training
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(N = 2000) and a test set (N = 4486). A proportion of glucose
and HbA1c specimens were mismatched by randomly switching
either HbA1c or glucose results. The outcome of interest was
correct classiﬁcation of vials as either ‘matched’ or ‘mismatched’.
The outcome was predicted using a Bayesian network that
encoded probabilistic relationships among analytes, self-reported
diabetes status and a latent ‘mismatch’ variable. Performance
was compared against an established approach LabRespond via
area under the receiver-operating characteristics curves (AUCs).
An AUC = 1.0 and 0.5 represents perfect prediction and random
guessing respectively. RESULTS: The network was predictive of
glucose and HbA1c mismatches that produced 20 mg/dL glucose
and 1 point HbA1c discrepancies between true and mismatched
scores (AUC = 0.84 (+/-0.03)). The network also identiﬁed
errors among those self-reporting diabetes (N = 329) AUC =
0.81 (+/-0.02) and predicted self-report of diabetes diagnosis
AUC = 0.95 (+/-0.01). The network also performed better
(z = 12.04, p < 0.001) than LabRespond (AUC = 0.76 +/- 0.01).
CONCLUSION: A Bayesian network that models probabilistic
relationships among analyte values can accurately identify mis-
matched specimens. The algorithm is best at identifying mis-
matches that result in a clinically signiﬁcant magnitude of error.
Information about diabetes diagnosis acted to reduce uncertainty
in a mismatch. Decision analysis may be have direct application
in reducing cost at point-of-care.
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OBJECTIVE: Human evaluation of laboratory errors is a costly
standard of practice. Automating error detection may reduce
costs and improve patient outcomes. To compare an automated
probabilistic approach (Bayesian network) to human expert
error detection in a pre-diabetic population. METHODS: Two
test sets (A and B) each N = 60 were generated from the results
of the Diabetes Prevention Program (DPP). Glucose values
were randomly drawn from a pre-diabetic distribution and
expected HbA1c score was estimated by the DPP based formula:
HbA1c = 4.22 + 0.1604 ¥ Glucose. In each test set, 37% of the
HbA1c scores were mismatched to generate vial labeling errors.
Eleven experts recruited from the American Academy of Clinical
Chemists and a Bayesian network evaluated the results to detect
mismatched vials. Six and ﬁve experts were assigned to test sets
A and B respectively. Receiver-Operating Characteristics (ROC)
curves were generated for each expert and for the Bayesian
network and area under the curves (AUCs) were compared via
null hypothesis testing. An AUC = 1 and 0.5 represents perfect
prediction and random guessing respectively. RESULTS: The
Bayesian network was predictive of glucose and HbA1c mis-
matches in both Test Set A (AUC = 0.86 (+/-0.05)) and Test Set
B (AUC = 0.93 (+/-0.04)). Expert performance was on average
worse in Test Sets A (AUC = 0.74 (+/-0.07)) and B (AUC = 0.76
(+/-0.07)). Individual analysis revealed that the network per-
formed signiﬁcantly better (z < 1.96, p < 0.05) than 7 of the 11
experts; in no case did the network perform worse than the
experts. CONCLUSION: A Bayesian network that models
probabilistic relationships among analyte values is often better
than laboratory experts at identifying laboratory errors. This
suggests that an automated program may help reduce costs and
improve patient outcomes in the laboratory.
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OBJECTIVE: Fibrin sealants are efﬁcacious in reducing peri-
operative bleeding during a variety of surgical procedures, which
may result in decreased hospital costs and lengths of stay (LOS).
This study sought to compare hospital costs and LOS by three
ﬁbrin sealants used in cardiac surgical procedures. METHODS:
Data were extracted from a large U.S. hospital-based, service-
level comparative database. Procedures were identiﬁed using
principal ICD-9 codes. Patients who received either FloSeal®
only or one of two comparison products (Gelfoam® + thrombin
or Surgicel® + thrombin) and were discharged from hospital
between April 1, 2003 and September 30, 2006 were included.
Costs were considered from the hospital perspective and were
derived from either reported actual costs or an estimated
calculation of costs-to-charges from the Medicare Cost Report.
Regression modeling with log transformation was employed to
compare differences in ﬁxed hospital costs (those insensitive to
volume), variable costs (those sensitive to volume), and post-
operative LOS. Control variables included age, gender, All
Patient Reﬁned-Diagnosis Related Group severity codes, region,
hospital teaching status, bed size, population served (urban
or rural), and primary payer. RESULTS: A total of 35,672
discharges were included. The regression models showed that
patients who received Gelfoam + thrombin had higher ﬁxed and
variable costs (+21% and +40%, p < 0.01, respectively) and
Surgicel + thrombin had higher ﬁxed and variable costs (+18%
and +14.5%, p < 0.01, respectively) compared to FloSeal. In
terms of ﬁxed costs, this amounted to an additional $21,803 for
Gelfoam + thrombin and an additional $19,208 for Surgicel +
thrombin cohorts. In variable costs, this amounted to an
additional $26,609 for Gelfoam + thrombin and $22,181 for
Surgicel + thrombin cohorts. All three cohorts had similar post-
operative LOS. CONCLUSION: FloSeal demonstrated cost
reduction in hospital stays for cardiac procedures, compared
to two other ﬁbrin sealants. Given small margins achieved by
hospitals today, cost-effective surgical aids with better or similar
outcomes should be considered in surgical service lines.
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OBJECTIVE: Fibrin sealants are used in a variety of surgical
procedures to reduce wound bleeding. This may consequently
decrease hospital costs and lengths of stay (LOS). This study
sought to compare costs and LOS following ﬁbrin sealant use
during spinal surgery. METHODS: Data were extracted from a
largeU.S. hospital-based, service-level comparative database. Pro-
cedures were identiﬁed using principal ICD-9 codes. Patients who
received either FloSeal® only or one of two comparison products
(Gelfoam® + thrombin or Surgicel® + thrombin) and were dis-
charged from hospital between April 1, 2003 and September 30,
2006 were included. Costs were considered from the hospital
perspective and were derived from either reported actual costs or
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